Maynard Um
-
-
-
-
-
-
-
Biogen (BIIB) PT Raised to $177 at Piper Sandler as 'Leqembi Continues to Ramp Well'
-
-
-
-
-
-
-
Biogen shares rise as Q4 earnings beat expectations, 2026 profit outlook strong
-
-
-
-
-
-
-
Biogen (BIIB) PT Lowered to $191 at Bernstein
-
-
-
-
-
-
-
UBS Assumes Biogen (BIIB) at Neutral
-
-
-
-
-
-
-
Eisai and Biogen present data showing LEQEMBI binding to toxic proteins
-
-
-
-
-
-
-
Biogen (BIIB): High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
-
-
-
-
-
-
-
Biogen (BIIB) PT Raised to $185 at Guggenheim
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

